Comments on the 340B Drug Pricing Integrity and Affordability for Patients Act Discussion Draft

The commenters raise concerns that 340B Drug Pricing Integrity and Affordability for Patients Act’s proposed rebate-based model would give manufacturers expanded authority to withhold 340B discounts and could strain covered entities’ cash flow, while the bipartisan SUSTAIN 340B Act’s clearinghouse-based approach would be a more effective alternative. They also argue that proposed geographic restrictions on contract pharmacies are too narrowly drawn, and call for pairing 340B reform with broader measures to lower drug prices, including strengthening Medicare drug price negotiation and addressing pharmaceutical patent abuses.